Reaction
Primary Progressive Multiple Sclerosis reporting signals
As of the last recalculation, Primary Progressive Multiple Sclerosis appears in 478 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is GLATIRAMER ACETATE (PRR 50.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Glatiramer Acetate | 61 | 50.8 | 50.9 |
| Ocrelizumab | 60 | 48.0 | 48.1 |
| Diroximel Fumarate | 11 | 41.1 | 41.2 |
| Dalfampridine | 54 | 36.8 | 36.9 |
| Natalizumab | 96 | 28.5 | 28.5 |
| Interferon Beta-1B | 11 | 25.6 | 25.6 |
| Dimethyl Fumarate | 62 | 25.1 | 25.1 |
| Interferon Beta-1A | 77 | 20.5 | 20.5 |
| Teriflunomide | 18 | 18.0 | 18.0 |
| Fingolimod Hcl | 33 | 17.8 | 17.8 |
| Siponimod | 3 | 14.7 | 14.7 |